MTSS2

Across TCGA pan-cancer cohorts, MTSS2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MTSS2 data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher MTSS2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MTSS2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

HNSC, CCRCC, and LUAD are the cancer types where MTSS2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Quartile	All	1.000	0.900	.010	17	view →
CCRCC	OS	Median	III,IV	0.945	0.675	.016	10	view →
LUAD	DFS	Quartile	II,III,IV	0.639	0.316	.033	5	view →
LSCC	DFS	Quartile	II,III,IV	0.361	1.000	.024	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MTSS2–HNSC (DFS)

Open the HNSC breakdown →